
NEWS & MEDIA
We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.
PRESS RELEASES
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
NEW YORK, July 14, 2021 -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its Board of Directors, effective...
BeyondSpring to Participate in the William Blair Biotech Focus Conference
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will participate in the William Blair Biotech...
BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development...
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA - Highlighted PROTECTIVE-2 Phase 3 data at two scientific conferences –...
BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its...
MEDIA
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.